Abstract
The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain, first emerged more than 20 years ago. The role for acetylcholinesterase (AChE) and its inhibition in this scheme has long been accepted, but findings from preclinical experiments and clinical trials have placed butyrylcholinesterase (BuChE) alongside AChE as an important contributor to the occurrence, symptoms, progression and responses to treatment in dementia. A number of new lines of evidence suggest that both cholinesterase inhibitors (ChEs) may have broader functions in the CNS than previously thought, which relate to both classical esterase activities of the enzymes as well as non-classical actions unrelated to their enzymatic function. Data suggest involvement of the ChEs in modulating glial activation, cerebral blood flow, the amyloid cascade, and tau phosphorylation. It has therefore been speculated that some actions of the ChEs could affect the underlying disease processes in Alzheimers disease (AD), and that pharmacological manipulation with ChE inhibitors may affect longterm disease progression. Focusing on new findings relating to BuChE, we review recent evidence that has extended knowledge into the roles of ChEs in health, disease and aging.
Keywords: acetylcholinesterase, butyrylcholinesterase, alzheimers disease, dementia, dementia with lewy bodies
Current Alzheimer Research
Title: Cholinesterases: Roles in the Brain During Health and Disease
Volume: 2 Issue: 3
Author(s): Clive G. Ballard, Nigel H. Greig, Angela L. Guillozet-Bongaarts, Albert Enz and Sultan Darvesh
Affiliation:
Keywords: acetylcholinesterase, butyrylcholinesterase, alzheimers disease, dementia, dementia with lewy bodies
Abstract: The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain, first emerged more than 20 years ago. The role for acetylcholinesterase (AChE) and its inhibition in this scheme has long been accepted, but findings from preclinical experiments and clinical trials have placed butyrylcholinesterase (BuChE) alongside AChE as an important contributor to the occurrence, symptoms, progression and responses to treatment in dementia. A number of new lines of evidence suggest that both cholinesterase inhibitors (ChEs) may have broader functions in the CNS than previously thought, which relate to both classical esterase activities of the enzymes as well as non-classical actions unrelated to their enzymatic function. Data suggest involvement of the ChEs in modulating glial activation, cerebral blood flow, the amyloid cascade, and tau phosphorylation. It has therefore been speculated that some actions of the ChEs could affect the underlying disease processes in Alzheimers disease (AD), and that pharmacological manipulation with ChE inhibitors may affect longterm disease progression. Focusing on new findings relating to BuChE, we review recent evidence that has extended knowledge into the roles of ChEs in health, disease and aging.
Export Options
About this article
Cite this article as:
Ballard G. Clive, Greig H. Nigel, Guillozet-Bongaarts L. Angela, Enz Albert and Darvesh Sultan, Cholinesterases: Roles in the Brain During Health and Disease, Current Alzheimer Research 2005; 2 (3) . https://dx.doi.org/10.2174/1567205054367838
DOI https://dx.doi.org/10.2174/1567205054367838 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Effects of Snake Venom Polypeptides on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Subject Index To Volume 2
Current Rheumatology Reviews Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Nanotechnology Advances in Brain Tumors: The State of the Art
Recent Patents on Anti-Cancer Drug Discovery Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Minocycline Inhibits mTOR Signaling Activation and Alleviates Behavioral Deficits in the Wistar Rats with Acute Ischemia stroke
CNS & Neurological Disorders - Drug Targets Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial: View of Excellent ROAD from the CAR
Current Alzheimer Research Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Non-Globular Structures of Tandem Repeats in Proteins
Protein & Peptide Letters Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets